Furthermore, our data suggest that enhanced Gadd45a expression may provide a means for eliminating BCR-ABL expressing LSCs, and thus targeting Gadd45a in combination with the BCR-ABL kinase inhibitor Imatinib could be an improved clinical approach to eliminate CML cells. Here, GADD45A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.